| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 06 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., November 5, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, tod... |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 23 Oct 2026 |
Form 4: Parker Geoffrey M., CHIEF FINANCIAL OFFICER
Sold 36,342 shares ($48.7K) |
| 21 Oct 2026 | 144 |
| 30 Sep 2026 | SCHEDULE 13D/A |
| 02 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 25 Aug 2026 |
Form 4: Douglas Earl Martin, SVP, General Counsel
Sold 29,697 shares ($63K) |
| 21 Aug 2026 | 144 |
| 20 Aug 2026 | EFFECT |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | S-3 |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
SOUTH SAN FRANCISCO, Calif., August 12, 2026 – Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, toda... |
| 07 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Jul 2026 |
Form 4: Roberts Zachary, President and CEO
Granted 134,530 Restricted Stock Unit · Granted 476,190 Stock Option (Right to buy) |
| 23 Jun 2026 |
Form 4: Kazam Joshua A, Director
Received 47,700 shares by exercise or conversion · Granted 95,400 Restricted Stock Unit |
| 23 Jun 2026 |
Form 4: Messemer Deborah M., Director
Granted 95,400 Restricted Stock Unit |
Loading...